Concentrated aqueous azalide formulations
View Patent ↗Provided is concentrated aqueous azithromycin formulation from about from about 2%-20%, and a method of making a concentrated aqueous azithromycin formulation which includes preparing and sterilizing a first solution comprising a strong base to form a sterilized solution, dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid, and adding the aqueous solution comprising the strong acid to the sterilized solution comprising the strong base. The strong acid has a pKa less than about −1.74 and the method is carried out without addition or use of a weak acid.
1. A method of making a concentrated aqueous azithromycin formulation comprising from about 2% to 20% azithromycin, said method comprising the steps of:
(a) preparing and sterilizing a first solution comprising a polymeric suspending agent the pH of which is adjusted with a strong base to form the first solution,
(b) dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid to form a second solution, and
(c) adding the second solution comprising the strong acid to the first solution adjusted with the strong base,
wherein the strong acid has a pKa less than about −1.74 and the method is carried out without addition or use of a weak acid.
2. The method of claim 1 , wherein the strong acid is hydrochloric acid.
3. The method of claim 1 wherein the strong base is sodium hydroxide.
4. The method of claim 1 , wherein the polymeric suspending agent is a lightly crosslinked carboxy-containing polymer.
5. The method of claim 1 wherein the aqueous azithromycin formulation further comprises an anti-inflammatory agent at a concentration of about 0.1% per weight of the total concentrated aqueous azithromycin formulation.
6. The method of claim 4 , wherein the aqueous solution further comprises a chitosan having a molecular weight from about 500 kDa to about 5,000 kDa in an amount from about 0.01% to about 1.0%.
7. A method of treating or preventing conditions associated with ocular infection comprising the steps of:
preparing a concentrated aqueous azithromycin formulation comprising from about 2% to 20% azithromycin, by sterilizing a first solution comprising a polymeric suspending agent the pH of which is adjusted with a strong base to form the first solution; dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid to form a second solution; and adding the second solution comprising the strong acid to the first solution adjusted with the strong base, wherein the strong acid has a pKa less than about −1.74 and the method is carried out without addition or use of a weak acid; and applying the formulation to the eye and/or tissue surrounding the eye in an amount effective to treat the eye.
8. The method of claim 7 , wherein the ocular infection is selected from the group consisting of: blepharitis, blepharconjunctivies, meibomianitis, acute or chronic hordeolum, chalazion, dacryocystitis, dacryoadenities, acne rosacea, bacterial conjunctivitis, ophthalmia neonatorum, trachoma, corneal ulcers, superficial and interstitial keratitis, keratoconjunctivitis, foreign bodies, post operative infections, endophthalmitis, and infectious uveitis.
9. The method of claim 7 , wherein the formulation is applied to the eye and/or the tissue surrounding the eye prior or post to an ocular surgical procedure.
10. The method of claim 7 , wherein the strong acid is hydrochloric acid.
11. A concentrated topical aqueous azalide antibiotic formulation comprising 2% to about 20% azithromycin and a polymeric suspending agent, said formulation made by dissolving azithromycin in a strong acid to form an azithromycin solution and then adding the azithromycin solution to a sterilized solution comprising the polymeric suspending agent, the pH of which is adjusted with a base, wherein the strong acid has a pKa less than about −1.74 and wherein the formulation is made in the absence of a weak acid.
12. The formulation of claim 11 , wherein the strong acid is hydrochloric acid.
13. The formulation of claim 11 wherein the strong base is sodium hydroxide.
14. The formulation of claim 11 , wherein the polymeric suspending agent is a lightly crosslinked carboxy-containing polymer.
15. The formulation of claim 14 wherein the polymeric suspending agent is Noveon AA-1.
16. The formulation of claim 14 further comprising an anti-inflammatory agent.
17. The formulation of claim 16 wherein the anti-inflammatory agent is dexamethasone.
18. The formulation of claim 17 , wherein the dexamethasone has a concentration of about 0.1% per weight of the total concentrated aqueous azithromycin formulation.
19. The formulation of claim 14 , wherein the aqueous solution further comprises a chitosan having a molecular weight from about 500 kDa to about 5,000 kDa in an amount from about 0.01% to about 1.0%.
20. The formulation of claim 14 , wherein the aqueous solution further comprises a chitosan having a molecular weight from about 50 kDa to about 100 kDa in an amount from about 0.01% to about 1.0%.
21. The formulation of claim 11 , wherein the weak acid is citric acid.